Read more
This book contains a series of contributions from internationally renowned academics with special expertise in one or other diseases which collectively are grouped under the heading myeloproliferative disorders. There have been many recent developments in understanding the pathophysiology and a number therapeutic innovations in this area. A feature of this book is the speed with which it has been produced - an important factor in this rapidly moving field.
List of contents
Chronic Myeloid Leukemia - A Brief History.- Bcr-Abl and Signal Transduction.- Chronic Myeloid Leukemia: Biology of Advanced Phase.- Clinical Features of CML.- Signal Transduction Inhibitors in Chronic Myeloid Leukemia.- Treatment with Tyrosine Kinase Inhibitors.- Allogeneic Transplantation for CML.- Autografting in Chronic Myeloid Leukemia.- Monitoring Disease Response.- New Therapies for Chronic Myeloid Leukemia.- Immune Therapy of Chronic Myelogenous Leukemia.- Therapeutic Strategies and Concepts of Cure in CML.- BCR-ABL-Negative Chronic Myeloid Leukemia.- Hypereosinophilic Syndrome.- Chronic Idiopathic Myelofibrosis.- Polycythemia Vera - Clinical Aspects.- Polycythemia Vera and Other Polycythemic Disorders - Biological Aspects.- Essential Thrombocythemia.
Summary
This book contains a series of contributions from internationally renowned academics with special expertise in one or other diseases which collectively are grouped under the heading myeloproliferative disorders. For the editors this term includes Ph-positive chronic myeloid leukemia but also the various Ph-negative variants, some of which provide fascinating insights into the molecular mechanisms of leukemia. There have been many recent developments in understanding the Pathophysiology and a number of therapeutic innovations in this area. One particular merit of this book is the speed with which it has been produced – an important factor in this very rapidly moving field.
Additional text
From the reviews:
"... a superb summary of the topic, is a modern synthesis of Dameshek’s adventurous thinking. ... Myeloproliferative Disorders is an important contribution to hematology. It arrives at a time when the study and treatment of these important diseases is at a crossroads, a time when hematologists everywhere have come to expect that the next great leap forward will come soon. For me, this book will sit on the shelf next to the first edition of Dameshek’s Leukemia. ..." (Robert Schwartz, New England Journal of Medicine, 356/ 24, June 2007)
"First identified and named by William Dameshek in 1951, myeloproliferative disorders have become ‘landmarks in the history of malignant disease … on which progress in understanding and treating other malignancies … and indeed solid tumors can be based.’ … it ‘should be of interest to medical students who find the specialty of hematology truly fascinating.’ For other physicians and for patients, this reference provides a needed understanding of avant-garde medical research." (William H. Wehrmacher, JAMA, Vol. 298, 2007)
Report
From the reviews:
"... a superb summary of the topic, is a modern synthesis of Dameshek's adventurous thinking. ... Myeloproliferative Disorders is an important contribution to hematology. It arrives at a time when the study and treatment of these important diseases is at a crossroads, a time when hematologists everywhere have come to expect that the next great leap forward will come soon. For me, this book will sit on the shelf next to the first edition of Dameshek's Leukemia. ..." (Robert Schwartz, New England Journal of Medicine, 356/ 24, June 2007)
"First identified and named by William Dameshek in 1951, myeloproliferative disorders have become 'landmarks in the history of malignant disease ... on which progress in understanding and treating other malignancies ... and indeed solid tumors can be based.' ... it 'should be of interest to medical students who find the specialty of hematology truly fascinating.' For other physicians and for patients, this reference provides a needed understanding of avant-garde medical research." (William H. Wehrmacher, JAMA, Vol. 298, 2007)
